Another day, another delay: FDA pushes back a second review for AbbVie's Rinvoq, this time in atopic dermatitis
AbbVie is continuing to look for ways to expand its Rinvoq franchise, betting the drug can be the next big thing once Humira’s patent runs out in a couple years. But on Friday the pharma ran into its second stumbling block at the FDA in the last few weeks.
Regulators have extended the review period for Rinvoq, also known as upadacitinib, in moderate to severe atopic dermatitis by three months until early in the third quarter, AbbVie announced Friday, citing the agency’s request for an updated benefit-risk profile. The delay follows a separate extension for the drug in psoriatic arthritis in mid-March.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.